Welcome to the peer-to-peer website where you can find links to third party education sites, including those offering CME credits, as well as view previously recorded sessions from global RDN experts on the latest clinical data, patient selection criteria and RDN procedure updates.
Click on the link to get to the below sections:
Wondr Medical
Wondr Medical Hub
An international resource with a range of scientific and practical information to explore and deploy Renal Denervation, including content in English, Italian, French, Portuguese, German, and Spanish.
Long-term efficacy and safety of renal denervation
Professor Felix Mahfoud presents 3 year data in patients on antihypertensive medications from the SPYRAL HTN-ON MED renal denervation trial presented at ACC 2022.
Renal Denervation: Moving from research to clinical practice
Authors of the 2021 ESH Position Paper on Renal Denervation discuss updated recommendations for RDN as another option for hypertension treatment options.
medscape
Medscape
RDN content from global experts offering CME credits through various activities.
How Much Blood Pressure Lowering Does it Take to Reduce CV Risk? The Answer May Surprise You
Drs. Cohen and Rahimi discuss the impact of a 5-mm Hg reduction in blood pressure on cardiovascular outcomes.
Listening to Patient Preferences to Overcome Poor Adherence: Is This the Key to Better BP Control?
Professors Weber and Pathak discuss how to incorporate patient preferences into RDN patient selection.
Clinical Data Videos
ACC.22: SPYRAL HTN-ON MED 3 year safety and efficacy
Professor Felix Mahfoud presents the long-term efficacy and safety of renal denervation on blood pressure in patients on antihypertension medications.
The Evidence for Radiofrequency Ablation as a Hypertension Treatment Option
Professor Andrew Sharp reviews the evidence for radiofrequency renal denervation focusing on the data supporting long-term safety and efficacy. Learn More
Clinical Event Reductions in High-Risk Hypertension Patients Treated with Renal Denervation
Professor Roland Schmieder presents evidence that blood pressure reductions in typical hypertensive patients on medications suggest a 26% relative risk reduction in Major Adverse Cardiac Events after radiofrequency renal denervation. Learn More
Leading with Evidence: Latest Data on RF Renal Denervation
EuroPCR 2021: Professor David Kandzari reviews the latest evidence for renal denervation as a 3rd pillar for hypertension treatment in addition to lifestyle modifications and medications, with a focus on upcoming evidence. Learn More
Real-world Outcomes with RF RDN from the Global Registry
EuroPCR 2021: Professor Felix Mahfoud discusses long-term safety, efficacy and patient selection insights from the largest study of renal denervation including 3000 patients in a real-world setting. Learn More
ESC 2021: Newest Renal Denervation Data and Patient Considerations
ESC 2021: Hear from the authors of the European Society of Hypertension Position Paper on Renal Denervation 2021 on the details of the latest expert consensus on patient selection.